We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The fourth-quarter results season has already seen a host of unwanted projects cleared from pharma companies’ pipelines as they tighten their focus on the projects with the most chance of a good return on investment.